Literature DB >> 7629224

Steroid 21-hydroxylase deficiency: genotype may not predict phenotype.

R C Wilson1, A B Mercado, K C Cheng, M I New.   

Abstract

Steroid 21-hydroxylase deficiency is the most frequent cause of congenital adrenal hyperplasia. We have determined the 21-hydroxylase genotype in 197 patients with congenital adrenal hyperplasia owing to 21-hydroxylase deficiency and assessed phenotypic characteristics based on 1) genital status with respect to virilization in females, 2) ACTH stimulation tests to evaluate the secretion of androgens and 17-hydroxyprogesterone, and 3) salt deprivation tests to precisely describe the phenotype with respect to aldosterone deficiency and salt wasting. After dividing our patients into 26 21-hydroxylase gene mutation-identical groups, we found that, in general, the patient's phenotype matched the severity of the genotype. However, in 13 of these groups, the genotype did not always predict the phenotype, even within families. This study, has demonstrated that the 10 most common mutations observed in the 21-hydroxylase gene result in phenotypes that are not always concordant with the genotype.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7629224     DOI: 10.1210/jcem.80.8.7629224

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  58 in total

Review 1.  Novel basic and clinical aspects of congenital adrenal hyperplasia.

Authors:  D P Merke; C A Camacho
Journal:  Rev Endocr Metab Disord       Date:  2001-08       Impact factor: 6.514

Review 2.  Congenital adrenal hyperplasia: epidemiology, management and practical drug treatment.

Authors:  D Merke; M Kabbani
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 3.  An overview of molecular diagnosis of steroid 21-hydroxylase deficiency.

Authors:  C E Keegan; A A Killeen
Journal:  J Mol Diagn       Date:  2001-05       Impact factor: 5.568

4.  Characterisation of CAH alleles with non-radioactive DNA single strand conformation polymorphism analysis of the CYP21 gene.

Authors:  A Bobba; A Iolascon; S Giannattasio; M Albrizio; A Sinisi; F Prisco; F Schettini; E Marra
Journal:  J Med Genet       Date:  1997-03       Impact factor: 6.318

5.  Mutation analysis of the CYP21A2 gene in the Iranian population.

Authors:  Bahareh Rabbani; Nejat Mahdieh; Mohammad Tahgi Haghi Ashtiani; Bagher Larijani; Mohammad Taghi Akbari; Maria New; Alan Parsa; Jan P Schouten; Ali Rabbani
Journal:  Genet Test Mol Biomarkers       Date:  2011-10-21

6.  Comprehensive genetic analysis of 182 unrelated families with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Authors:  Gabriela P Finkielstain; Wuyan Chen; Sneha P Mehta; Frank K Fujimura; Reem M Hanna; Carol Van Ryzin; Nazli B McDonnell; Deborah P Merke
Journal:  J Clin Endocrinol Metab       Date:  2010-10-06       Impact factor: 5.958

7.  Identification and functional characterization of a novel mutation P459H and a rare mutation R483W in the CYP21A2 gene in two Chinese patients with simple virilizing form of congenital adrenal hyperplasia.

Authors:  L Jiang; L L Song; H Wang; J L Wang; P P Wang; H B Zhou; X L Zhang
Journal:  J Endocrinol Invest       Date:  2011-07-12       Impact factor: 4.256

8.  Functional studies of two novel and two rare mutations in the 21-hydroxylase gene.

Authors:  M Barbaro; L Baldazzi; A Balsamo; S Lajic; T Robins; L Barp; P Pirazzoli; E Cacciari; A Cicognani; A Wedell
Journal:  J Mol Med (Berl)       Date:  2006-03-16       Impact factor: 4.599

9.  Genetic defects of the CYP21A2 gene in girls with premature adrenarche.

Authors:  N Skordis; C Shammas; A A P Phedonos; A Kyriakou; M Toumba; V Neocleous; L A Phylactou
Journal:  J Endocrinol Invest       Date:  2014-12-07       Impact factor: 4.256

10.  Extraadrenal 21-hydroxylation by CYP2C19 and CYP3A4: effect on 21-hydroxylase deficiency.

Authors:  Larissa G Gomes; Ningwu Huang; Vishal Agrawal; Berenice B Mendonça; Tania A S S Bachega; Walter L Miller
Journal:  J Clin Endocrinol Metab       Date:  2008-10-28       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.